Home›Loperamide Hydrochloride

Loperamide Hydrochloride

Also known as: Loperamide Hydrochloride

Route: Oral

Check Loperamide Hydrochloride Interactions →

6 interactions on record⛔ Black Box Warning

Loperamide Hydrochloride has 6 known drug interactions based on U.S. FDA drug labeling data. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Gemfibrozil, Itraconazole, Quinidine. Patients taking Loperamide Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 6
Major: 5
Moderate: 1

Major (5)

Loperamide Hydrochloride + Gemfibrozil— CYP2C8 inhibitor increases loperamide peak plasma concentration 1.6-fold and systemic exposure 2.2-fold, increasing risk…
Loperamide Hydrochloride + Itraconazole— CYP3A4 and P-glycoprotein inhibitor increases loperamide peak plasma concentration 2.9-fold and systemic exposure 3.8-fo…
Loperamide Hydrochloride + Quinidine— P-glycoprotein inhibitor increases loperamide plasma concentrations 2- to 3-fold with potential for enhanced CNS adverse…
Loperamide Hydrochloride + Ritonavir— P-glycoprotein inhibitor increases loperamide plasma concentrations 2- to 3-fold with potential for enhanced CNS adverse…
Loperamide Hydrochloride + Saquinavir— Loperamide decreases saquinavir exposure by 54%, potentially reducing therapeutic efficacy. Monitor saquinavir efficacy …

Moderate (1)

Loperamide Hydrochloride + Loperamide— Drug Interactions Nonclinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration …

Loperamide Hydrochloride + Gemfibrozil⚠️Major

CYP2C8 inhibitor increases loperamide peak plasma concentration 1.6-fold and systemic exposure 2.2-fold, increasing risk for cardiac adverse reactions.

Loperamide Hydrochloride + Itraconazole⚠️Major

CYP3A4 and P-glycoprotein inhibitor increases loperamide peak plasma concentration 2.9-fold and systemic exposure 3.8-fold, increasing risk for cardiac adverse reactions.

Loperamide Hydrochloride + Quinidine⚠️Major

P-glycoprotein inhibitor increases loperamide plasma concentrations 2- to 3-fold with potential for enhanced CNS adverse reactions.

Loperamide Hydrochloride + Ritonavir⚠️Major

P-glycoprotein inhibitor increases loperamide plasma concentrations 2- to 3-fold with potential for enhanced CNS adverse reactions.

Loperamide Hydrochloride + Saquinavir⚠️Major

Loperamide decreases saquinavir exposure by 54%, potentially reducing therapeutic efficacy. Monitor saquinavir efficacy closely.

Loperamide Hydrochloride + Loperamide🟡Moderate

Drug Interactions Nonclinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (16 mg single dose) with a 600 mg single dose of either quinidine or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2 to 3 fold increase in loperamide plasma levels. Due to the potential for enhanced central effects when loperamide is coadministered with quinidine and with ritonavir, caution should be exercised when loperamide is administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.